SCN7A

Sodium channel protein type 7 subunit alpha · Q01118 · SCN7A on Sugi Atlas →

17,809 patent compounds predicted against SCN7A, 12,300 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL160752	0.35	5/20
Noxiptiline (SCHEMBL49824)	0.49	2/20
Mexiletine (SCHEMBL16081)	1.00	1/20
(R)-Mexiletine (SCHEMBL16082)	1.00	1/20
Diltiazem (SCHEMBL17776)	1.00	1/20
Ajmaline (SCHEMBL18950)	1.00	1/20
Ajmaline (SCHEMBL34501)	1.00	1/20
Tetracaine (SCHEMBL34714)	1.00	1/20
Mibefradil (SCHEMBL39551)	1.00	1/20
Sertindole (SCHEMBL112092)	1.00	1/20
Cifenline (SCHEMBL122806)	1.00	1/20
Tedisamil (SCHEMBL157918)	1.00	1/20
Mibefradil (SCHEMBL120810)	0.99	1/20
Diltiazem (SCHEMBL15457)	0.98	1/20
Tetracaine (SCHEMBL24370)	0.97	1/20
Mexiletine (SCHEMBL42226)	0.96	1/20
Diltiazem (SCHEMBL120772)	0.83	1/20
Cifenline (SCHEMBL121044)	0.79	1/20
SCHEMBL281173	0.79	1/20
Clentiazem (SCHEMBL33909)	0.77	1/20

Clinical trials — most relevant to SCN7A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations	PHASE4	COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies	PHASE2	WITHDRAWN
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8	EARLY_PHASE1	COMPLETED
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
GABA Biomarkers in Dravet Syndrome	nan	RECRUITING
Probing the Role of Sodium Channels in Painful Neuropathies	nan	UNKNOWN
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity	nan	UNKNOWN
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.	nan	UNKNOWN
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Painful Channelopathies Study	nan	UNKNOWN
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SCN7A binder may also engage these)

Protein	Name	Similarity
B1AYL1	—	1.000	B1AYL1 →
F1LQQ7	—	1.000	F1LQQ7 →
P02719	—	0.994	P02719 →
P27732	—	0.992	P27732 →
Q6AXP6	—	0.992	Q6AXP6 →
Q9R053	—	0.992	Q9R053 →
SCN11A	Sodium channel protein type 11 subunit alpha	0.991	landscape →
Q8BVN3	—	0.991	Q8BVN3 →
P15390	—	0.991	P15390 →
Q62968	—	0.991	Q62968 →
Q28644	—	0.991	Q28644 →
Q28371	—	0.991	Q28371 →
Q80W99	—	0.991	Q80W99 →
O08562	—	0.990	O08562 →
Q62205	—	0.990	Q62205 →
P22002	—	0.990	P22002 →
SCN2A	Sodium channel protein type 2 subunit alpha	0.990	landscape →
CACNA1C	Voltage-dependent L-type calcium channel subunit alpha-1C	0.990	landscape →
SCN10A	Sodium channel protein type 10 subunit alpha	0.989	landscape →
O88457	—	0.989	O88457 →
O73700	—	0.989	O73700 →
Q6QIY3	—	0.989	Q6QIY3 →
Q25452	—	0.989	Q25452 →
CACNA1D	Voltage-dependent L-type calcium channel subunit alpha-1D	0.988	landscape →
P56698	—	0.988	P56698 →
SCN3A	Sodium channel protein type 3 subunit alpha	0.988	landscape →
Q02789	—	0.988	Q02789 →
Q2XVR6	—	0.988	Q2XVR6 →
CACNA1G	Voltage-dependent T-type calcium channel subunit alpha-1G	0.988	landscape →
O14234	—	0.988	O14234 →